WST financials
West Pharmaceutical Services, Inc. · end-of-day data as of Oct 16, 2026
West Pharmaceutical Services, Inc.
$384.02+17.1%
Buy · 17 analystsPT $391.16 +1.9%
WST reported revenue of $872M for the quarter ended Jun 30, 2026 (Q2 FY2026), up 13.8% from a year earlier. It posted diluted EPS of $2.15, free cash flow of $80.8M and a net margin of 17.7%.
Valuation
- P/E49.1x
- P/E vs own+23.8%
- P/E vs sector+74.4%
- FCF yield+1.6%
- Market cap$27.03B
Quarterly results
Q2 FY2026: Revenue +13.8% year over year, free cash flow 9.3% of revenue, operating margin 20.5%.
RevenueFree cash flow
| Q2 FY2026 | Jun 30, 2026 | $872M | 2.15 | $80.8M | 37.7% | 20.5% | 17.7% |
| Q1 FY2026 | Mar 31, 2026 | $845M | 1.92 | $47.2M | 35.1% | 21.0% | 16.4% |
| Q4 FY2025 | Dec 31, 2025 | $805M | 1.82 | $175M | 37.8% | 19.5% | 16.4% |
| Q3 FY2025 | Sep 30, 2025 | $804M | 1.93 | $134M | 36.5% | 21.6% | 17.4% |
| Q2 FY2025 | Jun 30, 2025 | $766M | 1.82 | $102M | 35.7% | 20.6% | 17.2% |
| Q1 FY2025 | Mar 31, 2025 | $698M | 1.23 | $58.1M | 33.3% | 18.4% | 12.9% |
| Q4 FY2024 | Dec 31, 2024 | $749M | 1.78 | $85.2M | 36.7% | 22.8% | 17.4% |
| Q3 FY2024 | Sep 30, 2024 | $747M | 1.85 | $98.8M | 35.5% | 22.5% | 18.2% |
| Q2 FY2024 | Jun 30, 2024 | $702M | 1.51 | $64.8M | 32.9% | 18.6% | 15.9% |
| Q1 FY2024 | Mar 31, 2024 | $695M | 1.55 | $27.6M | 33.3% | 18.3% | 16.6% |
| Q4 FY2023 | Dec 31, 2023 | $732M | 1.83 | $130M | 38.1% | 23.3% | 18.7% |
| Q3 FY2023 | Sep 30, 2023 | $748M | 2.14 | $134M | 38.7% | 25.6% | 21.6% |